Aronson M M, Miller R C, Hill R B, Nichols W W, Meadows A T
Mutat Res. 1982 Feb 22;92(1-2):291-307. doi: 10.1016/0027-5107(82)90232-9.
The incidence of chromosomal aberrations in banded karyotypes and of sister-chromatid exchanges (SCEs) was determined in the lymphocytes of survivors of childhood cancer as 2 parameters which are pertinent in assessing the genetic damage induced by chemotherapy. The proportion of cells with chromosome breakage or structural rearrangement-type aberration was 1 cell in 67 in a control group of 8 untreated cancer patients and 2 parents of cancer patients, 1 cell in 8 in 12 patients currently on therapy, and 1 cell in 50 in 17 patients sampled 6 months to 35 years post-treatment. The range of mean SCE levels per cell was 4.5-6.5 in the untreated cancer patients, 4.0-9.6 in non-cancer controls, 3.3-33.7 in patients on therapy, and 4.6-9.7 in post-therapy survivors. Considerably variability was observed between individuals with both SCE and breakage assays but therapy-induced increases in SCEs were not necessarily correlated with increased levels of aberrations arising from chromosomal breakage.
作为评估化疗所致遗传损伤的两个相关参数,对儿童癌症幸存者淋巴细胞中的带型核型染色体畸变发生率和姐妹染色单体交换(SCE)进行了测定。在8名未经治疗的癌症患者和2名癌症患者父母组成的对照组中,出现染色体断裂或结构重排型畸变的细胞比例为67个细胞中有1个;在12名正在接受治疗的患者中,该比例为8个细胞中有1个;在治疗后6个月至35年取样的17名患者中,该比例为50个细胞中有1个。未接受治疗的癌症患者每个细胞的平均SCE水平范围为4.5 - 6.5,非癌症对照组为4.0 - 9.6,接受治疗的患者为3.3 - 33.7,治疗后幸存者为4.6 - 9.7。在SCE和断裂检测中,个体之间观察到相当大的变异性,但治疗引起的SCE增加并不一定与染色体断裂引起的畸变水平增加相关。